Discover if this is a suitable investor for your startup. If they are we'll make a warm introduction for free. Otherwise, we'll connect you with matching investors.
Founded in 2015 and based in Barcelona, Spain, Capital Cell is an innovative alternative investment platform dedicated to the biotechnology and life sciences sectors. The firm aims to democratize access to high-impact investments, enabling individuals to contribute to advancements in human health. With a strong commitment to identifying and supporting early-stage companies, Capital Cell has established itself as a key player in the European investment landscape, particularly in Spain. The firm operates with a rigorous selection process, accepting only about 3% of the companies that apply for funding, ensuring that they back only the most promising ventures. This meticulous approach has allowed Capital Cell to build a diverse portfolio of companies that are not only innovative but also have the potential for global scalability and significant impact on human health.
Capital Cell specializes in investing in early-stage biotechnology and life sciences companies, with a strong emphasis on opportunities that demonstrate potential for global scalability and significant contributions to human health. The firm primarily focuses on pre-seed, seed, and seed-plus stages, allowing them to engage with startups at critical points in their development. Their investment strategy is characterized by a rigorous selection process, which ensures that only the most promising 3% of applicants receive funding. This focus on quality over quantity allows Capital Cell to maintain a high standard in their portfolio. The sectors of interest include biotech and healthcare, where they seek innovative solutions that address pressing health challenges. By leveraging a network of over 3,500 experts who analyze investment opportunities, Capital Cell is well-positioned to identify and support groundbreaking companies that align with their mission.
Capital Cell boasts a diverse portfolio of notable investments in the biotechnology and life sciences sectors. Among their key portfolio companies are **Oragen**, which specializes in unique RNA technology for treating intestinal inflammation, and **AbTx**, known for developing cancer treatments that penetrate solid tumors. Other significant investments include **2EyesVision**, which provides simulations for cataract surgery decisions, and **EVIS Bioscience**, focusing on gene delivery innovations. Additionally, **Kervalion** offers biological grafts for bone reconstruction, while **DynamicsVR** utilizes virtual reality and AI for rehabilitation automation. The firm also supports **FreeOx**, which develops therapies for stroke treatment, and **ALA Diagnostics**, known for its rapid diagnostic kit for Multiple Sclerosis. Other notable companies include **SoQut**, which innovates digital liver biopsy via MRI, **AXOLTIS Pharma**, focusing on drug candidates for ALS, and **Batea Oncology**, which creates devices for glioblastoma relapse. This diverse portfolio reflects Capital Cell's commitment to investing in transformative health solutions.
To pitch Capital Cell, founders should visit their website at capitalcell.com and submit their proposals. The firm prefers structured pitches that clearly outline the business model and market potential. They welcome both warm introductions and cold applications, but a well-prepared pitch is essential for consideration.
Capital Cell primarily invests in pre-seed, seed, and seed-plus stages. This focus allows them to engage with startups at critical points in their development, providing essential support as they grow.
Founders interested in pitching to Capital Cell can submit their proposals through their website at capitalcell.com. The firm prefers a structured pitch that outlines the business model, market potential, and how the innovation addresses a significant health challenge.
Capital Cell focuses on the biotechnology and healthcare sectors. They seek innovative solutions that have the potential for global scalability and significant impact on human health.
While specific check sizes are not disclosed, Capital Cell invests primarily in early-stage companies, which typically involves smaller investments compared to later-stage funding rounds.
Capital Cell primarily invests in Europe, with a strong focus on Spain. They aim to support local startups while also considering opportunities across the European market.
Capital Cell offers its portfolio companies access to a network of over 3,500 experts who analyze investment opportunities and provide guidance. This support is crucial for startups navigating the complexities of the biotechnology and healthcare sectors.
All trademarks, logos and brand names are the property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, trademarks, and brands does not imply endorsement.